Nonsense. It's a simple part of the same platform. It utilized one of the most advanced forms of new clinical trials, across different kinds of cancer. They will no doubt, once they have successfully gotten DCVax-L to market, work both on DCVax Direct as well as on ancillary deals with other companies to get real world data to validate DCVax-L for other tumors and hopefully as a tumor agnostic treatment. There is a lot of reform pending at the FDA, and those reforms bear directly on making it much easier and faster for getting both products to patients rapidly. I would not bet on your claim. Though it is possible NWBO will be bought out before it can do a lot more. That is a common circumstance when companies like this bring new treatment modalities with huge potential successfully to a phase 3 conclusion and toward marketing approval.
Bullish
Market Data 
Markets 
AI
